Catalent Begins $35m Controlled Release Expansion

By Dan Stanton

- Last updated on GMT

Related tags Pharmacology

Catalent Begins $35m Controlled Release Expansion
Catalent says customers are applying controlled release technology to transform drugs into better treatments across all stages of development as it expands its Kentucky manufacturing site.

Construction began on expanding Catalent’s controlled release drug manufacturing facility in Winchester, Kentucky yesterday in a $35m (€26m) project which will add 80,000 sq ft of manufacturing space and 90 new jobs to the site.

Catalent spokesperson Chris Halling spoke to saying the expansion is in response to client demand for higher quality, complex controlled release formulations across the drug development process, from pilot to commercial scale.

“Controlled release technology applications are being applied broadly to transform drugs into better treatments,”​ he said, “through improved therapeutic profiles, enhanced efficacy and safety, and increased patient compliance.”

He added: “It has also sparked resurgence in research and development for further product applications of innovator modified release formulations such as Zydis ODT (orally disintegrating tablet) fast-dissolve tablets.”

Zydis is a proprietary formulation from Catalent which requires no water to disperses instantly in the mouth, used, for example, as a form of drug delivery for Eli Lilly’s bipolar drug Zyprexa​.

Catalent Continues Fine-Tuning Its Operations

Halling also said the Winchester expansion followed a number of other investments from Catalent in order to meet growing customer demand, including last year’s expansion of its Schorndorf, Germany​ facility and a major capacity development at its Somerset, New Jersey headquarters.

As for the company’s strategy, Halling said it was focusing on growing core areas of the business, specifically: “Development solutions and advanced delivery technologies, clinical trial supplies, advanced blow/fill/seal aseptic delivery technology​, as well as offering integrated solutions for the development and supply of injectable biologics and complex pharmaceutical products.”

The contract manufacturer has been expanding its biologics offerings of late, with the license of ADC (antibody-drug conjugate) technology​ and the opening of a new biomanufacturing plant in Wisconsin​.

However, this direction was confirmed by Halling to be at the cost to other business areas including Catalent’s US commercial packaging operations which was sold last year to Frazier Healthcare​.

Commenting at the time, president of Catalent’s Medication Delivery Solutions segment Barry Littlejohns said the sale was “another step in advancing our strategy to focus on our leading drug development and delivery businesses in core segments.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us


View more